Salute e Benessere
$2.35 Billion by 2030: Why In Situ Hybridization Is Revolutionizing Molecular Diagnostics | MarketsandMarkets™
The global , valued at , is projected to reach , growing at a CAGR of . This growth is driven by the expanding role of ISH in , , and . Technological innovations—including multiplex ISH, high-sensitivity probes, and automation—are enabling more accurate, efficient, and spatially resolved gene expression analysis in both clinical and research settings. From oncology to neuroscience, ISH is paving the way for advanced diagnostics and next-generation therapeutic strategies.
In Situ Hybridization methods such as and are increasingly used to detect patient-specific genetic markers at the single-cell level. These techniques offer greater specificity and spatial resolution than conventional assays. For instance, ( Feb 2025 ) now enables differentiation between psoriasis and atopic dermatitis based on biopsy-derived immunologic markers—transforming diagnostics for millions with chronic skin conditions.
Key players and are leveraging ISH to support oncology, gene therapy, and neurodegenerative disease research, further embedding these tools in drug development pipelines and personalized treatment planning.
ISH technologies address a number of persistent issues in molecular and histopathological diagnostics:
For example, ( Jan 2025 ) enhances lymphoma subtype detection, representing a breakthrough in ISH-based molecular diagnostics.
While North America leads with the largest market share due to established infrastructure and funding, rapid growth is forecasted in the Asia Pacific , driven by rising cancer incidence, government funding, and diagnostic modernization.
Key momentum drivers include:
The ISH market is consolidated, with 5 major players holding of global market share:
Recent innovations include:
Despite promising advances, high costs and technical complexity remain barriers:
Not "Is ISH useful?"—but rather:
As genomics shifts toward , in situ hybridization is evolving from a research tool into a cornerstone of precision healthcare. It's not just about detection anymore—it's about localization, integration, and transformation of diagnostics.
In the future of molecular medicine, .
F. Hoffmann-La Roche Ltd ( Switzerland ), Danaher (US), Abbott (US), Bio-Techne (US), Thermo Fisher Scientific (US), Bioview ( Israel ), Biocare Medical (US), Agilent Technologies (US), QIAGEN ( Germany ), CytoTest Inc. (US), Genemed Biotechnologies (US), ZytoVision GmbH ( Germany ), Abnova ( Taiwan )
For more information,
Get access to the latest updates on and
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, , and . With a , we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our , which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo; https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/2-35-billion-by-2030-why-in-situ-hybridization-is-revolutionizing-molecular-diagnostics--marketsandmarkets-302499852.html